IDO1 and triple-negative breast carcinoma: As reported by a phase I/II trial (NCT02178722), a novel combined therapy of epacadostat (IDO1 inhibitor) and pembrolizumab (PD-1 inhibitor) was well tolerated and showed antitumor activity in patients with triple-negative breast cancer [55].